Seminars in Hematology
Volume 40, Issue 1 , Pages 59-71 , January 2003

Allogeneic stem cell transplantation for chronic myeloid leukemia

References 

  1. Alyea EP, Soiffer RJ, Canning C, et al.  Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood. 1998;91:3671–3680
  2. Barrett AJ, van Rhee F. Graft-versus-leukaemia. Baillieres Clin Haematol. 1997;10:337–355
  3. Barrett AJ. Mechanisms of the graft-vs-leukemia reaction. Stem Cells. 1997;15:248–258
  4. Barrett AJ, Mavroudis D, Tisdale J, et al.  T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft versus-leukemia effect. Bone Marrow Transplant. 1998;21:543–551
  5. Barrett AJ, Ringden O, Zhang MJ, et al.  Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia. Blood. 2000;95:3323–3327
  6. Barta A, Denes R, Masszi T, et al.  Remarkably reduced transplant-related complications by dibromomannitol nonmyeloablative conditioning before allogeneic bone marrow transplantation in chronic myeloid leukemia. Acta Haematol. 2001;105:64–70
  7. Beelen DW, Elmaagacli AH, Schaefer UW. The adverse influence of pretransplant interferon-alpha (IFN-alpha) on transplant outcome after marrow transplantation for chronic phrase chronic myelogenous leukemia increases with the duration of IFN-alpha exposure. Blood. 1999;93:1779–1790
  8. Brandenburg U, Gottlieb D, Bradstock K. Antileukemic effects of rapid cyclosporin withdrawal in patients with relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. Leuk Lymphoma. 1998;31:545–550
  9. Carreras E, Tomas JF, Sanz G, et al.  Unrelated donor bone marrow transplantation as treatment for chronic myeloid leukemia: the Spanish experience. The Chronic Myeloid Leukemia Subcommittee of the GETH. Grupo Espanol de Trasplante Hemopoyetico. Haematologica. 2000;85:530–538
  10. Champlin R, Khouri I, Shimoni A, et al.  Harnessing graft-versus-malignancy: Non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol. 2000;111:18–29
  11. Childs R, Epperson D, Bahceci E, et al.  Molecular remission of chronic myeloid leukaemia following a non-myeloablative allogeneic peripheral blood stem cell transplant: in vivo and in vitro evidence for a graft-versus-leukaemia effect. Br J Haematol. 1999;107:396–400
  12. Clark RE, Dodi IA, Hill SC, et al.  Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood. 2001;98:2887–2893
  13. Clave E, Molldrem J, Hensel N, et al.  Donor-recipient polymorphism of the proteinase 3 gene: a potential target for T-cell alloresponses to myeloid leukemia. Immunotherapy. 1999;22:1–6
  14. Clift RA, Buckner CD, Thomas ED, et al.  Marrow transplantation for chronic myeloid leukemia: A randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood. 1994;84:2036–2043
  15. Craddock C, Szydlo RM, Dazzi F, et al.  Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: The case for tailored graft-versus-host disease prophylaxis. Br J Haematol. 2001;112:228–236
  16. Craddock C, Szydlo RM, Klein JP, et al.  Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission. Blood. 2000;96:86–90
  17. Davies SM, DeFor TE, McGlave PB, et al.  Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. Am J Med. 2001;110:404–405
  18. Devergie A, Apperley JF, Labopin M, et al.  European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1997;20:11–19
  19. Dini G, Lamparelli T, Rondelli R, et al.  Unrelated donor marrow transplantation for chronic myelogenous leukaemia. Br J Haematol. 1998;102:544–552
  20. Drobyski WR, Hessner MJ, Klein JP, et al.  T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation. Blood. 1999;94:434–441
  21. Elmaagacli AH, Beelen DW, Opalka B, et al.  The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrow. Blood. 1999;94:381–383
  22. Elmaagacli AH, Beelen DW, Trenn G, et al.  Induction of a graft-versus leukemia reaction by cyclosporin A withdrawal as immunotherapy for leukemia relapsing after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1999;23:771–777
  23. Elmaagacli AH, Runkel K, Steckel N, et al.  A comparison of chimerism and minimal residual disease between four different allogeneic transplantation methods in patients with chronic myelogenous leukemia in first chronic phase. Bone Marrow Transplant. 2001;27:809–815
  24. Elmaagacli AH, Basoglu S, Peceny R, et al.  Improved disease-free-survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia. Blood. 2002;99:1130–1135
  25. Falkenburg JH, Smit WM, Willemze R:. Cytotoxic T-lymphocyte (CTL) responses against acute or chronic myeloid leukemia. Immunol Rev. 1997;157:223–230
  26. Falkenburg JH, Wafelman AR, Joosten P, et al.  Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood. 1999;94:1201–1208
  27. Gale RP, Horowitz MM, Ash RC, et al.  Identical-twin bone marrow transplants for leukemia. Ann Intern Med. 1994;120:646–652
  28. Gao L, Bellantuono I, Elsasser A, et al.  Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood. 2000;95:2198–2203
  29. Gardiner N, Lawler M, O'Riordan JM, et al.  Monitoring of lineage-specific chimaerism allows early prediction of response following donor lymphocyte infusions for relapsed chronic myeloid leukaemia. Bone Marrow Transplant. 1998;21:711–719
  30. Giralt S, Hester J, Huh Y, et al.  CD8+-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Graft vs. leukemia without graft vs. host disease. Blood. 1995;86:4337–4343
  31. Giralt S, O'Brien S, Talpaz M, et al.  Interferon-alpha and interleukin-2 as treatment for leukemia relapse after allogeneic bone marrow transplantation. Cytokines Mol Ther. 1995;1:115–122
  32. Giralt S, Thall PF, Khouri I, et al.  Melphalan and purine analog-containing preparative regimens: Reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001;97:631–637
  33. Gratwohl A, Hermans J, van Biezen A, et al.  Splenic irradiation before bone marrow transplantation for chronic myeloid leukaemia. Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol. 1996;95:494–500
  34. Griesshammer M, Arnold R, Bangerter M, et al.  Chronic myeloid leukemia in accelerated phase: treatment results with conventional chemotherapy and allogeneic bone marrow transplantation in 96 patients. Eur J Haematol. 1998;61:7–13
  35. Hansen JA, Gooley TA, Martin PJ, et al.  Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med. 1998;338:962–968
  36. Hartman AR, Williams SF, Dillon JJ. Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: A meta-analysis. Bone Marrow Transplant. 1998;22:439–443
  37. Hehlmann R, Hochhaus A, Kolb HJ, et al.  Interferon-alpha before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure. Blood. 1999;94:3668–3677
  38. Hessner M, Endean D, Casper J, et al.  Use of unrelated marrow grafts compensates for reduced graft versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia. Blood. 1995;86:3896–3987
  39. Higano CS, Chielens D, Raskind W, et al.  Use of α-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation. Blood. 1997;90:2549–2554
  40. Horowitz MM, Gale RP, Sondel PM, et al.  Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555–562
  41. Horowitz MM. Summary slides. IBMTR Newsletter. 2002;9:4–11
  42. Jabro G, Koc Y, Boyle T, et al.  Role of splenic irradiation in patients with chronic myeloid leukemia undergoing allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2000;6:211–213
  43. Jiang YZ, Barrett AJ, Goldman JM, et al.  Evidence for natural killer cell modulation of a graft-versus-graft-versus-leukaemia effect without graft-versus-host disease following allogeneic bone marrow transplantation. Ann Hematol. 1997;74:1–6
  44. Kaeda J, Chase A, Goldman JM. Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukaemia. Acta Haematol. 2002;107:64–75
  45. Kim I, Park S, Kim BK, et al.  Allogeneic bone marrow transplantation for chronic myeloid leukemia: A retrospective study of busulfan-Cytoxan versus total body irradiation-Cytoxan as preparative regimen in Koreans. Clin Transplant. 2001;15:167–172
  46. Kitzis A, Brizard F, Dascalescu C, et al.  Persistence of transcriptionally silent BCR-ABL rearrangements in chronic myeloid leukemia patients in sustained complete cytogenetic remission. Leuk Lymphoma. 2001;42:933–944
  47. Kolb H-J, Mitmuller J, Clemm Ch, et al.  Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76:2462–2465
  48. Kolb HJ, Schattenberg A, Goldman JM, et al.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86:2041–2050
  49. Konstantinidou P, Szydlo RM, Chase A, et al.  Cytogenetic status pre-transplant as a predictor of outcome post bone marrow transplantation for chronic myelogenous leukaemia. Bone Marrow Transplant. 2000;25:143–146
  50. Kroger N, Zabelina T, Kruger W, et al.  Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients. Bone Marrow Transplant. 2001;27:349–354
  51. Lee SJ, Klein JP, Anasetti C, et al.  The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase. Blood. 2001;98:3205–3211
  52. Mackinnon S, Papadopoulos E, Carabasi M, et al.  Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus host disease. Blood. 1995;86:1261–1268
  53. McGlave PB, Shu XO, Wen W, et al.  Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. Blood. 2000;95:2219–2225
  54. McSweeney PA, Niederwieser D, Shizuru JA, et al.  Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97:3390–3400
  55. Mehta J, Powles R, Kulkarni S, et al.  Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: single-center experience of 32 adult patients. Bone Marrow Transplant. 1997;20:129–135
  56. Molldrem JJ, Lee PP, Wang C, et al.  A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res. 1999;59:2675–2681
  57. Molldrem JJ, Lee PP, Wang C, et al.  Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 2000;6:1018–1023
  58. Morariu-Zamfir R, Rocha V, Devergie A, et al.  Influence of CD34(+) marrow cell dose on outcome of HLA-identical sibling allogeneic bone marrow transplants in patients with chronic myeloid leukaemia. Bone Marrow Transplant. 2001;27:575–580
  59. Morton AJ, Gooley T, Hansen JA, et al.  Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. Blood. 1998;92:394–3401
  60. Mutis T, Gillespie G, Schrama E, et al.  Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Nat Med. 1999;5:839–842
  61. Novitzky N, Rubinstein R, Hallett JM, et al.  Bone marrow transplantation depleted of T cells followed by repletion with incremental doses of donor lymphocytes for relapsing patients with chronic myeloid leukemia: A therapeutic strategy. Transplantation. 2000;69:1358–1363
  62. Olavarria E, Kanfer E, Szydlo R, et al.  Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood. 2001;97:1560–1565
  63. Olavarria E, Craddock C, Dazzi F, et al.  Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. Blood. 2002;99:3861–3862
  64. Pigneux A, Tanguy ML, Michallet M, et al.  Prior treatment with alpha interferon does not adversely affect the outcome of allogeneic transplantation for chronic myeloid leukaemia. Br J Haematol. 2002;116:193–201
  65. Pinilla-Ibarz J, Cathcart K, Scheinberg DA. CML vaccines as a paradigm of the specific immunotherapy of cancer. Blood Rev. 2000;14:111–120
  66. Pocock C, Szydlo R, Davis J, et al.  Stem cell transplantation for chronic myeloid leukaemia: The role of infused marrow cell dose. Hematol J. 2001;2:265–272
  67. Raanani P, Dazzi F, Sohal J, et al.  The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. Br J Haematol. 1997;99:945–950
  68. Radich JP, Gooley T, Bryant E, et al.  The significance of bcr-abl molecular detection in chronic myeloid leukemia patients “late,” 18 months or more after transplantation. Blood. 2001;98:1701–1707
  69. Raiola AM, Van Lint MT, Lamparelli T, et al.  Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age. Br J Haematol. 2000;109:716–721
  70. Reiter E, Greinix HT, Keil F, et al.  Long-term follow-up of patients after related- and unrelated-donor bone marrow transplantation for chronic myelogenous leukemia. Ann Hematol. 1999;78:507–513
  71. Ringden O, Remberger M, Ruutu T, et al.  Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: Long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group. Blood. 1999;93:2196–2201
  72. Robinson SP, Mackinnon S, Slavin S, et al: A retrospective study of non-myeloablative allogeneic stem cell transplantation for lymphoma. Bone Marrow Transplantation 27:65, (suppl 1, abstr)
  73. Roman J, Martin C, Torres A, et al.  Importance of mixed chimerism to predict relapse in persistently BCR/ABL positive long survivors after allogeneic bone marrow transplantation for chronic myeloid leukemia. Leuk Lymphoma. 1998;28:541–550
  74. Ruggeri L, Capanni M, Urbani E, et al.  Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097–2100
  75. Sandmaier BM, Niederwieser D, McSweeney PA, et al.  Induction of molecular remissions in chronic myelogenous leukemia (CML) with nonmyeloablative HLA-identical sibling allografts. Blood. 2000;96(supp1 1, abstr):201
  76. Schattenberg A, Preijers F, Mensink E, et al.  Survival in first or second remission after lymphocyte-depleted transplantation for Philadelphia chromosome-positive CML in first chronic phase. Bone Marrow Transplant. 1997;19:1205–1212
  77. Schmitz N, Barrett J. Optimizing engraftment—Source and dose of stem cells. Semin Hematol. 2002;39:3–14
  78. Sehn LH, Alyea EP, Weller E, et al.  Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: Impact of donor lymphocyte infusion. J Clin Oncol. 1999;17:561–568
  79. Serrano J, Roman J, Sanchez J, et al.  Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210(BCR-ABL) and p190(BCR ABL) after allogeneic bone marrow transplantation for chronic myeloid leukemia: Increasing mixed myeloid chimerism and p190(BCR-ABL) detection precede cytogenetic relapse. Blood. 2000;95:2659–2665
  80. Sharathkumar A, Thornley I, Saunders EF, et al.  Allogeneic bone marrow transplantation in children with chronic myelogenous leukemia. J Pediatr Hematol Oncol. 2002;24:215–219
  81. Siegert W, Beyer J, Kingreen D, et al.  Treatment of relapse after allogeneic bone marrow transplantation with unmanipulated G-CSF-mobilized peripheral blood stem cell preparation. Bone Marrow Transplant. 1998;22:579–583
  82. Slavin S, Nagler A, Naparstek E, et al.  Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756–763
  83. Slavin S, Ackerstein A, Morecki S, et al.  Immunotherapy of relapsed resistant chronic myelogenous leukemia post allogeneic bone marrow transplantation with alloantigen pulsed donor lymphocytes. Bone Marrow Transplant. 2001;28:795–798
  84. Socie G, Clift RA, Blaise D, et al.  Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: Long-term follow-up of 4 randomized studies. Blood. 2001;98:3569–3574
  85. Speiser DE, Hermans J, van Biezen A, et al.  Haploidentical family member transplants for patients with chronic myeloid leukaemia: A report of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 1997;19:1197–1203
  86. Sullivan KM, Weiden PL, Storb R, et al.  Influence of acute and chronic graft-versus-host disease after relapse and survival after bone marrow transplantation from HLA identical siblings as treatment of acute and chronic leukemia. Blood. 1989;73:1720–1722
  87. Szydlo R, Goldman JM, Klein JP, et al.  Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol. 1997;15:1767–1777
  88. Tomas JF, Lopez-Lorenzo JL, Requena MJ, et al.  Absence of influence of prior treatment with interferon on the outcome of allogeneic bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant. 1998;22:47–51
  89. van Rhee F, Kolb HJ. Donor leukocyte transfusions for leukemic relapse. Curr Opin Hematol. 1995;2:423–430
  90. van Rhee F, Szydlo RM, Hermans J, et al.  Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: A report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1997;20:553–560
  91. van Rhee F, Savage D, Blackwell J, et al.  Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: Equal efficacy of lymphocytes from sibling and matched unrelated donors. Bone Marrow Transplant. 1998;21:1055–1061
  92. Vela-Ojeda J, Tripp-Villanueva F, Sanchez-Cortes E, et al.  Allogeneic bone marrow transplantation for chronic myeloid leukemia: A single center experience. Arch Med Res. 2000;31:206–209
  93. Vey N, Balatzentko G, Lafage M, et al.  Survey of early disappearance of BCR/ABL fusion transcript after allogeneic or autologous stem cell transplantation for chronic myelogenous leukemia. Leuk Lymphoma. 2001;42:945–952
  94. Visani G, Rosti G, Bandini G, et al.  Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia. Br J Haematol. 2000;109:722–728
  95. Warren EH, Greenberg PD, Riddell SR. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood. 1998;91:2197–2207
  96. Weisdorf DJ, Anasetti C, Antin J, et al.  Allogeneic bone marrow transplantation for chronic myelogenous leukemia: Comparative analysis of unrelated versus matched sibling donor transplantation. Blood. 2002;99:1971–1977
  97. Zorn E, Orsini E, Wu CJ, et al.  A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells. Transplantation. 2001;71:1131–1137
  98. Zuffa E, Bandini G, Bonini A, et al.  Prior treatment with alpha-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia. Haematologica. 1998;83:231–236

☆ Address reprint requests to John Barrett, MD, Hematology Branch, NIH-NHLB1, Building 10 Room 7C103, 9000 Rockville Pike, Bethesda MD 20892-0003.

☆☆ This is a US government work. There are no restrictions on its use.

PII: S0037-1963(03)70043-2

Seminars in Hematology
Volume 40, Issue 1 , Pages 59-71 , January 2003

Article Tools

* Image Usage & Resolution